Summary
Definition
History and exam
Key diagnostic factors
- chronic mood disorder lasting greater than 2 years
- depressive symptoms present for most of the day, most days
- no periods of euthymia in the past 2 years (1 year for children or adolescents)
- symptoms of major depression may be continuously present for 2 or more years
Other diagnostic factors
- no symptoms of mania/hypomania or schizophrenia
- absence of underlying medical conditions, medication use, or substance abuse that could cause the mood disorder
- fatigue or low energy
- low self-esteem
- poor concentration or difficulty making decisions
- feelings of hopelessness
- poor appetite or overeating
- sleep disturbance
Risk factors
- positive family history
- female sex
Diagnostic tests
1st tests to order
- medical evaluation
- CBC
- thyroid function tests
- metabolic panel
- vitamin D
- Patient Health Questionnaire (PHQ-9)
- Beck Depression Inventory (BDI)
- Quick Inventory of Depressive Symptoms (QIDS)
Tests to consider
- vitamin B12
- urine test
- ECG
Treatment algorithm
all patients
Contributors
Authors
David J. Hellerstein, MD
Professor of Clinical Psychiatry
Columbia University Medical Center
Director, Depression Evaluation Service
New York State Psychiatric Institute
New York
NY
Disclosures
DJH has received research grants (through the Research Foundation for Mental Hygiene) from Compass Pathways, Relmada, Marinus, Intracellular Therapies, Beckley Foundation, and from Velocity Foundation (through Columbia University). DJH serves on scientific advisory board for Reset Pharmaceuticals. DJH has received royalties from Johns Hopkins University Press, and Columbia University Press.
Acknowledgements
Dr David J. Hellerstein would like to gratefully acknowledge Dr David L. Dunner, a previous contributor to this topic.
Disclosures
DLD has received grant support from Cyberonics. DLD has received fees for consulting from: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Forest, Cyberonics, Roche Diagnostics, Cypress, Corcept, Janssen, Novartis, Shire, Somerset, Otsuka, Healthcare Technology Sys, Jazz Pharma, Sanofi-Aventis, and MedAvante. DLD is on the Speaker's Bureau for: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Organon, Jazz Pharma, Neuronetics, and Astra-Zeneca. DLD is an author of several references cited in this topic.
Peer reviewers
Dean F. MacKinnon, MD
Associate Professor
John Hopkins University
Baltimore
MD
Disclosures
DK declares that he has no competing interests.
James H. Kocsis, MD
Professor
Weill Cornell Medicine
New York
NY
Disclosures
JK has professionally collaborated with the authors.
Neil Nixon, BSc, MMedSci, MBBS, FRCPsych
Associate Professor in Psychiatry
Institute of Mental Health
University of Nottingham
Nottingham
UK
Disclosures
NN is a member of the current NICE GDG for depression in adults. NN has met with Jansen in a non-remunerative capacity. He has various research collaborations including a funded trial and is author on a number of papers.
Differentials
- Major depressive disorder
- Bipolar disorders (bipolar I, bipolar II, bipolar disorder not otherwise specified)
- Cyclothymic disorder
More DifferentialsGuidelines
- Screening for depression and suicide risk in adults: US Preventive Services Task Force recommendation statement
- Depression in adults: treatment and management
More GuidelinesPatient information
Depression in adults: what is it?
Persistent depressive disorder (long-term depression)
More Patient information- Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer